Patrick T. Wood

Patrick T. Wood

Auto-generated profile, based on publicly available information

Patrick T. Wood

Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, OH (P.T.W., K.L.D., J.E.S.).

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in Shock
Verified
Journal Article
Open access
YFYoke Lin Fung
Yoke Lin Fung
CSChristopher C. Silliman
Christopher C. Silliman
RMRobyn M. Minchinton
Robyn M. Minchinton
PWPeter Wood
Peter Wood
John Francis FraserJohn Francis Fraser
John Francis Fraser
Studies during and immediately post-cardiopulmonary bypass (CPB) surgery have revealed that neutrophils (PMNs) are pivotal to post-CPB inflammation and innate immunity. The aim of this study was to investigate the effects of CPB on the PMN phenotype and respiratory burst function over a longer post-CPB period (up to day 5). Blood samples were collected pre-CPB and on days 1, 3, and 5 post-CPB from 20 patients. Changes to PMN surface expression of CD16, CD62L, CD11b, CD18, and CD43, and PMN respiratory burst activity were measured, together with the white blood cell count and absolute PMN count. Cardiopulmonary bypass induced neutrophilia on days 1 and 3. One day post-CPB, CD16 expression reached a nadir (P = 0.001), and platelet-activating factor-induced CD18 increase was depressed (P < 0.05). Three days post-CPB, CD43 expression peaked (P < 0.05), with a concomitant resistance to N-formyl-Met-Leu-Phe-induced CD11b upregulation (P < 0.05). The PMN respiratory burst activity declined continuously post-CPB until day 5. Neutrophilia on days 1 and 3 was associated with changes to surface molecules expression that may reduce PMN activation response. This study demonstrated that CPB depresses the respiratory burst activity of host PMNs for an extraordinarily longer period of at least 5 days even after neutrophilia had resolved. Collectively, the changes portray an autoprotective yet responsive homeostatic balance.

1 January 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
JCJoo Hee Choi
Joo Hee Choi
PWPatrick T. Wood
Patrick T. Wood
JHJoshua B. Holmes
Joshua B. Holmes
KDKatherine L. Dominic
Katherine L. Dominic
CRCristobal Dos Remedios
Cristobal Dos Remedios
JSJulian E. Stelzer
Julian E. Stelzer
This is the first study to provide a detailed mechanistic comparison of omecamtiv mecarbil (OM) and danicamtiv (DN) in failing and nonfailing human myocardium. These findings have clinical implications and the potential to inform the clinical utility of myosin activators in the heart failure setting.

20 May 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
IFIan Flinn
Ian Flinn
RJRichard H. C. Van Der Jagt
Richard H. C. Van Der Jagt
BKBrad S. Kahl
Brad S. Kahl
PWPeter Wood
Peter Wood
THTim E. Hawkins
Tim E. Hawkins
JBJohn McEvoy Burke
John McEvoy Burke
8537 Background: BR was previously reported to be statistically noninferior to R-CVP/R-CHOP for complete response rate in the treatment of patients with indolent NHL or MCL. Evaluation of time-to-event outcomes is immature. This subanalysis reports response by histology. Methods: Indolent NHL or MCL was histologically confirmed <6 months before study enrollment in patients who were therapy-naïve. Patients were stratified according to predetermined standard treatment (R-CHOP or RECVP) and lymphoma type, then assigned to receive BR (28-day cycles: bendamustine 90 mg/m2 on days 1 and 2, rituximab 375 mg/m2on day 1) or standard treatment (21-day cycles at standard doses) for 6-8 cycles. Responses were assessed by a blinded independent review committee. The primary efficacy measure was noninferiority of BR complete response (CR) rate for evaluable patients with ≥1 postbaseline efficacy assessment. If the noninferiority threshold was met, superiority was assessed. Secondary measures included tolerability. Results: Of 447 patients enrolled in the study, 213 receiving BR and 206 receiving R-CHOP/R-CVP were evaluable with postbaseline data (Table). BR achieved a statistically noninferior CR rate compared with R-CHOP/R-CVP in patients with indolent NHL and MCL. Conclusions: In patients with treatment-naïve indolent NHL and MCL, BR achieved the primary endpoint of noninferior CR rate. Most CR rates were numerically, but not significantly, higher with BR. Small subgroup results should be interpreted with caution. Support: Teva BPP R&D, Inc. Clinical trial information: NCT00877006.

10 October 2025 in Circulation Research
Verified
Journal Article
Closed access
JBJeffrey S. Bennett
Jeffrey S. Bennett
PWPatrick T. Wood
Patrick T. Wood
KDKatherine L. Dominic
Katherine L. Dominic
CMChristine S. Moravec
Christine S. Moravec
Kenneth CampbellKenneth Campbell
Kenneth Campbell
JSJulian E. Stelzer
Julian E. Stelzer